Anixa Biosciences free cash flow ANIX

Cash from operations less capital spending, by quarter and over the last twelve months, from 2011.

Anixa Biosciences' free cash flow was −$6.2M over the twelve months to Oct 31, 2020.

In its latest quarter, Q4 FY20, it was −$1.4M.

Free cash flow over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	Free cash flow	On a year earlier	Last 12 months
Q4 FY20	Oct 31, 2020	−$1.4M	n/a	−$6.2M
Q3 FY20	Jul 31, 2020	−$1.3M	n/a	−$6.1M
Q2 FY20	Apr 30, 2020	−$1.6M	n/a	−$5.5M
Q1 FY20	Jan 31, 2020	−$1.9M	n/a	n/a
Q4 FY19	Oct 31, 2019	−$1.3M	n/a	n/a
Q3 FY19	Jul 31, 2019	−$640.1K	n/a	n/a
Q4 FY18	Oct 31, 2018	−$1M	n/a	−$4.3M
Q3 FY18	Jul 31, 2018	−$1.2M	n/a	−$4M
Q2 FY18	Apr 30, 2018	−$751.8K	n/a	−$4.1M
Q1 FY18	Jan 31, 2018	−$1.3M	n/a	−$4.4M
Q4 FY17	Oct 31, 2017	−$752.6K	n/a	−$3.8M
Q3 FY17	Jul 31, 2017	−$1.3M	n/a	−$3.8M

Companies in Drug Manufacturers - General nearest Anixa Biosciences' size, closest first, today.

Company	Free cash flow yield
ANIXAnixa Biosciences	n/m
LFVNLifevantage	9.1%
SPROSpero Therapeutics	n/m
NATRNatures Sunshine Products	8.5%
ATNMActinium Pharmaceuticals	n/m
ARVNArvinas	−43.7%
PBYIPuma Biotechnology	7.2%
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	5.6%
CRMDCorMedix	n/m
COLLCollegium Pharmaceutical	n/m
Peer median	7.2%